TuHURA Biosciences (HURA) Expected to Announce Earnings on Friday

Key Points

• TuHURA is projected to report earnings on May 15 with analysts forecasting ($0.12) EPS for the quarter; the company missed the prior quarter (reported ($0.13) vs. consensus ($0.12)) and analysts expect $0 EPS for the current and next fiscal years.
• Shares opened at $2.40 and were down about 5.5%, valuing the company at roughly $152.8M with a 12‑month range of $0.41–$4.20; the consensus rating is a Moderate Buy with an average analyst target of $9.00.
• TuHURA is a clinical‑stage biotechnology firm that leverages a proprietary high‑dimensional proteomics platform to translate protein signatures into drug targets and develop first‑in‑class therapies.

TuHURA Biosciences (NASDAQ:HURA - Get Free Report) is projected to announce its resultson Friday, May 15th. Analysts expect the company to announce earnings of ($0.12) per share for the quarter.

TuHURA Biosciences (NASDAQ:HURA - Get Free Report) last issued its quarterly earnings results on Tuesday, March 31st. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01). On average, analysts expect TuHURA Biosciences to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

TuHURA Biosciences Trading Down 5.5%

TuHURA Biosciences stock opened at $2.40 on Friday. The company has a market capitalization of $152.83 million, a price-to-earnings ratio of -3.81 and a beta of -0.01. TuHURA Biosciences has a 12 month low of $0.41 and a 12 month high of $4.20. The stock's 50 day moving average is $2.05 and its 200-day moving average is $1.60.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on HURA shares. Weiss Ratings reissued a "sell (e+)" rating on shares of TuHURA Biosciences in a report on Tuesday, April 21st. Citigroup started coverage on shares of TuHURA Biosciences in a research note on Monday, April 27th. They issued an "outperform" rating on the stock. Citizens Jmp started coverage on shares of TuHURA Biosciences in a research note on Monday, April 27th. They issued a "market outperform" rating and a $9.00 price objective for the company. HC Wainwright reissued a "buy" rating and issued a $10.00 price objective on shares of TuHURA Biosciences in a report on Tuesday, February 3rd. Finally, Rodman & Renshaw assumed coverage on shares of TuHURA Biosciences in a research report on Wednesday, April 15th. They issued a "buy" rating for the company. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $9.00.

Hedge Funds Weigh In On TuHURA Biosciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC bought a new stake in shares of TuHURA Biosciences in the third quarter worth $26,000. JPMorgan Chase & Co. bought a new position in TuHURA Biosciences during the 2nd quarter worth $27,000. Invesco Ltd. bought a new position in TuHURA Biosciences during the 2nd quarter worth approximately $30,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of TuHURA Biosciences during the second quarter worth $31,000. Finally, Bank of America Corp DE bought a new position in TuHURA Biosciences during the fourth quarter worth $59,000. 0.62% of the stock is currently owned by institutional investors and hedge funds.

TuHURA Biosciences Company Profile

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company's core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA's approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.